DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RADIUM RA-223 DICHLORIDE
Clinical Trials for Radium Ra-223 Dichloride
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00699751 | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases | Completed | Bayer | Phase 3 | ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases. |
NCT01516762 | Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | No longer available | Bayer | N/A | This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product. |
NCT01618370 | Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | Completed | Bayer | Phase 3 | This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Radium Ra-223 Dichloride
Condition Name
Clinical Trial Locations for Radium Ra-223 Dichloride
Trials by Country
Clinical Trial Progress for Radium Ra-223 Dichloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Radium Ra-223 Dichloride
Sponsor Name